- Home
- CLSD vs SRTS Comparison
CLSD vs SRTS Comparison
Compare CLSD & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- SRTS
- Stock Information
- Founded
- CLSD 2011
- SRTS 2010
- Country
- CLSD United States
- SRTS United States
- Employees
- CLSD N/A
- SRTS N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- CLSD Health Care
- SRTS Health Care
- Exchange
- CLSD Nasdaq
- SRTS Nasdaq
- Market Cap
- CLSD 68.4M
- SRTS 75.5M
- IPO Year
- CLSD 2016
- SRTS 2016
- Fundamental
- Price
- CLSD $0.46
- SRTS $5.54
- Analyst Decision
- CLSD Hold
- SRTS Strong Buy
- Analyst Count
- CLSD 4
- SRTS 3
- Target Price
- CLSD $4.33
- SRTS $11.67
- AVG Volume (30 Days)
- CLSD 12.7M
- SRTS 103.3K
- Earning Date
- CLSD 08-11-2025
- SRTS 08-07-2025
- Dividend Yield
- CLSD N/A
- SRTS N/A
- EPS Growth
- CLSD N/A
- SRTS N/A
- EPS
- CLSD N/A
- SRTS 0.11
- Revenue
- CLSD $3,764,000.00
- SRTS $39,488,000.00
- Revenue This Year
- CLSD $143.33
- SRTS $4.33
- Revenue Next Year
- CLSD N/A
- SRTS $26.74
- P/E Ratio
- CLSD N/A
- SRTS $48.49
- Revenue Growth
- CLSD N/A
- SRTS 24.75
- 52 Week Low
- CLSD $0.29
- SRTS $4.01
- 52 Week High
- CLSD $1.65
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- CLSD 34.58
- SRTS 65.61
- Support Level
- CLSD $0.29
- SRTS $5.21
- Resistance Level
- CLSD $0.62
- SRTS $5.92
- Average True Range (ATR)
- CLSD 0.11
- SRTS 0.32
- MACD
- CLSD -0.02
- SRTS 0.14
- Stochastic Oscillator
- CLSD 25.16
- SRTS 78.53
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.